MetaVia Inc. — Director's Dealing 2016

Aug 12, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Gemphire Therapeutics Inc. (GEMP)
CIK: 0001638287
Period of Report: 2016-08-10

Reporting Person: Gullans Steven R. Ph.D. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-10	Common Stock	C	306025	$6.7059	Acquired	306025	Indirect
2016-08-10	Common Stock	P	500000	$10.00	Acquired	806025	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-10	8% Convertible Subordinated Promissory Note	$6.7059	C		Disposed		Common Stock (306025)	Indirect

Footnotes

F1: The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F2: The note was issued in the original principal amount of $2,000,000. The outstanding principal and $52,164 of accrued interest on the note automatically converted into shares of Common Stock immediately prior to the closing of the Company's initial public offering.